H.C. Wainwright Sticks to Their Buy Rating for Mind Medicine (MNMD)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of ...
Strategic Catalysts and Market Potential Drive Buy Rating for Milestone Pharmaceuticals’ CARDAMYST
Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) and keeping the ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research ...
Q3 EPS Forecast for Arrowhead Pharmaceuticals Cut by Analyst
Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a ...